---
document_datetime: 2025-12-02 04:51:45
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/exforge.html
document_name: exforge.html
version: success
processing_time: 0.182188
conversion_datetime: 2025-12-28 05:00:31.136542
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Exforge

[RSS](/en/individual-human-medicine.xml/66972)

##### Authorised

This medicine is authorised for use in the European Union

amlodipine / valsartan Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Exforge](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-81172)
- [More information on Exforge](#more-information-on-exforge-837)
- [More information on Exforge](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

This is a summary of the European public assessment report (EPAR) for Exforge. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Exforge.

Expand section

Collapse section

## What is Exforge?

Exforge is a medicine that contains two active substances, amlodipine and valsartan. It is available as tablets (5 mg amlodipine and 80 mg valsartan; 5 mg amlodipine and 160 mg valsartan; 10 mg amlodipine and 160 mg valsartan).

## What is Exforge used for?

Exforge is used in patients who have essential hypertension (high blood pressure) that is not adequately controlled on either amlodipine or valsartan taken alone. 'Essential' means that the hypertension has no obvious cause.

The medicine can only be obtained with a prescription.

## How is Exforge used?

Exforge is taken by mouth as one tablet once a day with some water. The dose of Exforge to be used depends on the doses of amlodipine or valsartan that the patient was taking before. The patient may need to take separate tablets or capsules before switching to the combination tablet.

## How does Exforge work?

Exforge contains two active substances, amlodipine and valsartan. Both are anti-hypertensive medicines that have been available separately in the European Union (EU) since the mid-1990s. They work in similar ways to reduce blood pressure by allowing the blood vessels to relax. By lowering the blood pressure, the risks associated with high blood pressure, such as having a stroke, are reduced.

Amlodipine is a calcium channel blocker. It blocks special channels on the surface of cells called calcium channels, through which calcium ions normally enter the cells. When calcium ions enter the cells in the muscles of blood vessel walls, this causes contraction. By reducing the flow of calcium into the cells, amlodipine prevents the cells from contracting and this helps the blood vessels to relax.

Valsartan is an 'angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II. Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels). By blocking the receptors to which angiotensin II normally attaches, valsartan stops the hormone having an effect, allowing the blood vessels to widen.

## How has Exforge been studied?

Because amlodipine and valsartan have been used for many years, the company presented information on the two substances from earlier studies and the scientific literature, as well as new studies that used a combination of the two active substances.

Five main studies involving nearly 5,200 patients, mostly with mild to moderate hypertension, were carried out. Two studies (involving almost 3,200 patients) compared amlodipine, valsartan or a combination of both substances with placebo (a dummy treatment). Two studies (involving 1,891 patients) compared the combination in patients whose hypertension was not adequately controlled with either 10 mg amlodipine or 160 mg valsartan. The fifth, smaller study compared the combination with lisinopril and hydrochlorothiazide (another combination used to treat hypertension) in 130 patients with severe hypertension. In all studies, the main measure of effectiveness was the reduction in diastolic blood pressure (the blood pressure measured between two heartbeats). The blood pressure was measured in 'millimetres of mercury' (mmHg).

The company also presented evidence that the levels of amlodipine and valsartan in the blood were the same in people taking Exforge and people taking the separate medicines.

## What benefit has Exforge shown during the studies?

The combination of amlodipine and valsartan was more effective at reducing blood pressure than placebo or either valsartan or amlodipine taken alone. In the studies comparing the combination in patients who were already taking either amlodipine or valsartan, the blood pressure in patients taking valsartan alone had fallen by 6.6 mmHg after eight weeks, compared with 9.6 and 11.4 mmHg in the patients adding 5 or 10 mg amlodipine, respectively. Patients taking amlodipine alone had a fall of 10.0 mmHg, compared with 11.8 mmHg in the patients adding 160 mg valsartan.

## What is the risk associated with Exforge?

The most common side effects with Exforge (seen in between 1 and 10 patients in 100) are headache, nasopharyngitis (inflammation of the nose and throat), influenza (flu), hypokalaemia (low blood potassium levels), various types of oedema (swelling), fatigue (tiredness), flushing (reddening), asthenia (weakness) and hot flushes. For the full list of all side effects reported with Exforge, see the package leaflet.

Exforge must not be used in patients who are hypersensitive (allergic) to amlodipine or other medicines in the 'dihydropyridine derivatives' class, to valsartan, or to any of the other ingredients. It must not be used in women who are more than three months pregnant. Its use during the first three months of pregnancy is not recommended. Exforge must not be used in patients who have severe liver or bile problems, patients with certain heart problems and patients with severe hypotension (low blood pressure). Exforge must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension) in patients with type 2 diabetes or in patients with moderate or severe kidney impairment. For the full list of restrictions, see the package leaflet.

## Why has Exforge been approved?

The CHMP decided that Exforge's benefits are greater than its risks and recommended that it be given marketing authorisation.

## Other information about Exforge

The European Commission granted a marketing authorisation valid throughout the EU for Exforge on 17 January 2007.

For more information about treatment with Exforge, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Exforge : EPAR - Summary for the public

English (EN) (75.24 KB - PDF)

**First published:** 05/05/2009

**Last updated:** 05/08/2015

[View](/en/documents/overview/exforge-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-954)

български (BG) (103.37 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/bg/documents/overview/exforge-epar-summary-public_bg.pdf)

español (ES) (76.66 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/es/documents/overview/exforge-epar-summary-public_es.pdf)

čeština (CS) (102.86 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/cs/documents/overview/exforge-epar-summary-public_cs.pdf)

dansk (DA) (75.85 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/da/documents/overview/exforge-epar-summary-public_da.pdf)

Deutsch (DE) (77.22 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/de/documents/overview/exforge-epar-summary-public_de.pdf)

eesti keel (ET) (74.87 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/et/documents/overview/exforge-epar-summary-public_et.pdf)

ελληνικά (EL) (102.7 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/el/documents/overview/exforge-epar-summary-public_el.pdf)

français (FR) (77.33 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/fr/documents/overview/exforge-epar-summary-public_fr.pdf)

hrvatski (HR) (97.01 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/hr/documents/overview/exforge-epar-summary-public_hr.pdf)

italiano (IT) (75.91 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/it/documents/overview/exforge-epar-summary-public_it.pdf)

latviešu valoda (LV) (98.41 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/lv/documents/overview/exforge-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (98.3 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/lt/documents/overview/exforge-epar-summary-public_lt.pdf)

magyar (HU) (96.1 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/hu/documents/overview/exforge-epar-summary-public_hu.pdf)

Malti (MT) (102.55 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/mt/documents/overview/exforge-epar-summary-public_mt.pdf)

Nederlands (NL) (75.58 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/nl/documents/overview/exforge-epar-summary-public_nl.pdf)

polski (PL) (102.76 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/pl/documents/overview/exforge-epar-summary-public_pl.pdf)

português (PT) (76.22 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/pt/documents/overview/exforge-epar-summary-public_pt.pdf)

română (RO) (98.4 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/ro/documents/overview/exforge-epar-summary-public_ro.pdf)

slovenčina (SK) (101.35 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/sk/documents/overview/exforge-epar-summary-public_sk.pdf)

slovenščina (SL) (92.51 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/sl/documents/overview/exforge-epar-summary-public_sl.pdf)

Suomi (FI) (75.47 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/fi/documents/overview/exforge-epar-summary-public_fi.pdf)

svenska (SV) (75.86 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

05/08/2015

[View](/sv/documents/overview/exforge-epar-summary-public_sv.pdf)

## Product information

Exforge : EPAR - Product information

English (EN) (457.31 KB - PDF)

**First published:** 05/05/2009

**Last updated:** 19/11/2025

[View](/en/documents/product-information/exforge-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-563)

български (BG) (539.51 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/bg/documents/product-information/exforge-epar-product-information_bg.pdf)

español (ES) (495.64 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/es/documents/product-information/exforge-epar-product-information_es.pdf)

čeština (CS) (521.45 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/cs/documents/product-information/exforge-epar-product-information_cs.pdf)

dansk (DA) (499.17 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/da/documents/product-information/exforge-epar-product-information_da.pdf)

Deutsch (DE) (506.62 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/de/documents/product-information/exforge-epar-product-information_de.pdf)

eesti keel (ET) (475.76 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/et/documents/product-information/exforge-epar-product-information_et.pdf)

ελληνικά (EL) (554.63 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/el/documents/product-information/exforge-epar-product-information_el.pdf)

français (FR) (533.04 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/fr/documents/product-information/exforge-epar-product-information_fr.pdf)

hrvatski (HR) (501.61 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/hr/documents/product-information/exforge-epar-product-information_hr.pdf)

íslenska (IS) (477.99 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/is/documents/product-information/exforge-epar-product-information_is.pdf)

italiano (IT) (498.98 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/it/documents/product-information/exforge-epar-product-information_it.pdf)

latviešu valoda (LV) (544.96 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/lv/documents/product-information/exforge-epar-product-information_lv.pdf)

lietuvių kalba (LT) (520.83 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/lt/documents/product-information/exforge-epar-product-information_lt.pdf)

magyar (HU) (534.79 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/hu/documents/product-information/exforge-epar-product-information_hu.pdf)

Malti (MT) (587.61 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/mt/documents/product-information/exforge-epar-product-information_mt.pdf)

Nederlands (NL) (507.63 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/nl/documents/product-information/exforge-epar-product-information_nl.pdf)

norsk (NO) (485.83 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/no/documents/product-information/exforge-epar-product-information_no.pdf)

polski (PL) (566.37 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/pl/documents/product-information/exforge-epar-product-information_pl.pdf)

português (PT) (515.04 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/pt/documents/product-information/exforge-epar-product-information_pt.pdf)

română (RO) (522.73 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/ro/documents/product-information/exforge-epar-product-information_ro.pdf)

slovenčina (SK) (532.36 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/sk/documents/product-information/exforge-epar-product-information_sk.pdf)

slovenščina (SL) (503.63 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/sl/documents/product-information/exforge-epar-product-information_sl.pdf)

Suomi (FI) (516.88 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/fi/documents/product-information/exforge-epar-product-information_fi.pdf)

svenska (SV) (494.29 KB - PDF)

**First published:**

05/05/2009

**Last updated:**

19/11/2025

[View](/sv/documents/product-information/exforge-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000309769 19/11/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Exforge : EPAR - All Authorised presentations

English (EN) (142.51 KB - PDF)

**First published:** 20/05/2008

**Last updated:** 05/08/2010

[View](/en/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-291)

български (BG) (87.19 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/bg/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_bg.pdf)

español (ES) (20.46 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/es/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_es.pdf)

čeština (CS) (48.88 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/cs/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (19.87 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/da/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (19.75 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/de/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (20.18 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/et/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (83.89 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/el/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_el.pdf)

français (FR) (20.12 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/fr/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (50.22 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/hr/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (36.62 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/is/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_is.pdf)

italiano (IT) (19.58 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/it/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (86.16 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/lv/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (88.04 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/lt/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (88.18 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/hu/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (87.44 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/mt/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (19.27 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/nl/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (40.05 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/no/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_no.pdf)

polski (PL) (51.26 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/pl/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_pl.pdf)

português (PT) (19.45 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/pt/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_pt.pdf)

română (RO) (83.24 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/ro/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (49.6 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/sk/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (20.49 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/sl/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (20.96 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/fi/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (19.78 KB - PDF)

**First published:**

20/05/2008

**Last updated:**

05/08/2010

[View](/sv/documents/all-authorised-presentations/exforge-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Exforge Active substance

- valsartan
- amlodipine (as amlodipine besilate)

International non-proprietary name (INN) or common name

- amlodipine
- valsartan

Therapeutic area (MeSH) Hypertension Anatomical therapeutic chemical (ATC) code C09DB01

### Pharmacotherapeutic group

Agents acting on the renin-angiotensin system

### Therapeutic indication

Treatment of essential hypertension.

Exforge is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.

## Authorisation details

EMA product number EMEA/H/C/000716 Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Marketing authorisation issued 16/01/2007 Revision 35

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Exforge : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (329.22 KB - PDF)

**First published:** 12/02/2025

**Last updated:** 19/11/2025

[View](/en/documents/procedural-steps-after/exforge-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Exforge : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (5.84 MB - PDF)

**First published:** 05/05/2009

**Last updated:** 12/02/2025

[View](/en/documents/procedural-steps-after/exforge-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Angiotensin-II-receptor antagonists (sartans) : Scientific conclusions - Impact of the Article 5(3) scientific opinion on nitrosamines

Adopted

English (EN) (119.28 KB - PDF)

**First published:** 05/07/2021

[View](/en/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_en.pdf)

[Other languages (22)](#file-language-dropdown-844)

български (BG) (145.18 KB - PDF)

**First published:**

05/07/2021

[View](/bg/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_bg.pdf)

español (ES) (125.85 KB - PDF)

**First published:**

05/07/2021

[View](/es/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_es.pdf)

čeština (CS) (139.02 KB - PDF)

**First published:**

05/07/2021

[View](/cs/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_cs.pdf)

dansk (DA) (126.81 KB - PDF)

**First published:**

05/07/2021

[View](/da/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_da.pdf)

Deutsch (DE) (131.05 KB - PDF)

**First published:**

05/07/2021

[View](/de/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_de.pdf)

eesti keel (ET) (123.85 KB - PDF)

**First published:**

05/07/2021

[View](/et/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_et.pdf)

ελληνικά (EL) (139.5 KB - PDF)

**First published:**

05/07/2021

[View](/el/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_el.pdf)

français (FR) (127.12 KB - PDF)

**First published:**

05/07/2021

[View](/fr/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_fr.pdf)

hrvatski (HR) (142.87 KB - PDF)

**First published:**

05/07/2021

[View](/hr/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_hr.pdf)

italiano (IT) (126.56 KB - PDF)

**First published:**

05/07/2021

[View](/it/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_it.pdf)

latviešu valoda (LV) (147.7 KB - PDF)

**First published:**

05/07/2021

[View](/lv/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_lv.pdf)

lietuvių kalba (LT) (148.34 KB - PDF)

**First published:**

05/07/2021

[View](/lt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_lt.pdf)

magyar (HU) (137.17 KB - PDF)

**First published:**

05/07/2021

[View](/hu/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_hu.pdf)

Malti (MT) (151.21 KB - PDF)

**First published:**

05/07/2021

[View](/mt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_mt.pdf)

Nederlands (NL) (127.53 KB - PDF)

**First published:**

05/07/2021

[View](/nl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_nl.pdf)

polski (PL) (137.7 KB - PDF)

**First published:**

05/07/2021

[View](/pl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_pl.pdf)

português (PT) (128.87 KB - PDF)

**First published:**

05/07/2021

[View](/pt/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_pt.pdf)

română (RO) (143.59 KB - PDF)

**First published:**

05/07/2021

[View](/ro/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_ro.pdf)

slovenčina (SK) (135.07 KB - PDF)

**First published:**

05/07/2021

[View](/sk/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sk.pdf)

slovenščina (SL) (149.74 KB - PDF)

**First published:**

05/07/2021

[View](/sl/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sl.pdf)

Suomi (FI) (125.84 KB - PDF)

**First published:**

05/07/2021

[View](/fi/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_fi.pdf)

svenska (SV) (126.99 KB - PDF)

**First published:**

05/07/2021

[View](/sv/documents/scientific-conclusion/angiotensin-ii-receptor-antagonists-sartans-scientific-conclusions-impact-article-53-scientific-opinion-nitrosamines_sv.pdf)

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report - Impact of the Article 5(3) scientific opinion on nitrosamines

Adopted

Reference Number: EMA/47245/2021

English (EN) (362.31 KB - PDF)

**First published:** 02/03/2021

[View](/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report-impact-article-53-scientific-opinion-nitrosamines_en.pdf)

Exforge-H-C-716-A31-0098 : EPAR - Scientific conclusions

English (EN) (99.42 KB - PDF)

**First published:** 24/05/2019

[View](/en/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_en.pdf)

[Other languages (22)](#file-language-dropdown-138)

български (BG) (136.15 KB - PDF)

**First published:**

24/05/2019

[View](/bg/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_bg.pdf)

español (ES) (98.31 KB - PDF)

**First published:**

24/05/2019

[View](/es/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_es.pdf)

čeština (CS) (131.08 KB - PDF)

**First published:**

24/05/2019

[View](/cs/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_cs.pdf)

dansk (DA) (96.12 KB - PDF)

**First published:**

24/05/2019

[View](/da/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_da.pdf)

Deutsch (DE) (100.2 KB - PDF)

**First published:**

24/05/2019

[View](/de/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_de.pdf)

eesti keel (ET) (94.4 KB - PDF)

**First published:**

24/05/2019

[View](/et/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_et.pdf)

ελληνικά (EL) (142.79 KB - PDF)

**First published:**

24/05/2019

[View](/el/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_el.pdf)

français (FR) (97.56 KB - PDF)

**First published:**

24/05/2019

[View](/fr/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_fr.pdf)

hrvatski (HR) (125.02 KB - PDF)

**First published:**

24/05/2019

[View](/hr/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_hr.pdf)

italiano (IT) (95.54 KB - PDF)

**First published:**

24/05/2019

[View](/it/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_it.pdf)

latviešu valoda (LV) (130.68 KB - PDF)

**First published:**

24/05/2019

[View](/lv/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_lv.pdf)

lietuvių kalba (LT) (130.84 KB - PDF)

**First published:**

24/05/2019

[View](/lt/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_lt.pdf)

magyar (HU) (119.82 KB - PDF)

**First published:**

24/05/2019

[View](/hu/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_hu.pdf)

Malti (MT) (133.78 KB - PDF)

**First published:**

24/05/2019

[View](/mt/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_mt.pdf)

Nederlands (NL) (99.3 KB - PDF)

**First published:**

24/05/2019

[View](/nl/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_nl.pdf)

polski (PL) (130.65 KB - PDF)

**First published:**

24/05/2019

[View](/pl/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_pl.pdf)

português (PT) (96.47 KB - PDF)

**First published:**

24/05/2019

[View](/pt/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_pt.pdf)

română (RO) (128.25 KB - PDF)

**First published:**

24/05/2019

[View](/ro/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_ro.pdf)

slovenčina (SK) (119.14 KB - PDF)

**First published:**

24/05/2019

[View](/sk/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_sk.pdf)

slovenščina (SL) (124.14 KB - PDF)

**First published:**

24/05/2019

[View](/sl/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_sl.pdf)

Suomi (FI) (97.12 KB - PDF)

**First published:**

24/05/2019

[View](/fi/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_fi.pdf)

svenska (SV) (96.85 KB - PDF)

**First published:**

24/05/2019

[View](/sv/documents/scientific-conclusion/exforge-h-c-716-a31-0098-epar-scientific-conclusions_sv.pdf)

Angiotensin-II-receptor antagonists (sartans) Article 31 referral - CHMP assessment report

Adopted

Reference Number: EMA/217823/2019

English (EN) (531.32 KB - PDF)

**First published:** 02/05/2019

[View](/en/documents/variation-report/angiotensin-ii-receptor-antagonists-sartans-article-31-referral-chmp-assessment-report_en.pdf)

Exforge-H-C-716-A31-0067 : EPAR - Scientific conclusions, grounds for variation to the terms of the marketing authorisations and detailed explanation of the scientific grounds for the differences from the PRAC recommenda...

English (EN) (48.81 KB - PDF)

**First published:** 01/10/2014

**Last updated:** 01/10/2014

[View](/en/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_en.pdf)

[Other languages (22)](#file-language-dropdown-674)

български (BG) (87.49 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/bg/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_bg.pdf)

español (ES) (50.51 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/es/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_es.pdf)

čeština (CS) (82.81 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/cs/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_cs.pdf)

dansk (DA) (49.01 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/da/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_da.pdf)

Deutsch (DE) (53.54 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/de/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_de.pdf)

eesti keel (ET) (50.6 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/et/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_et.pdf)

ελληνικά (EL) (89.54 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/el/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_el.pdf)

français (FR) (51.91 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/fr/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_fr.pdf)

hrvatski (HR) (80.12 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/hr/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_hr.pdf)

italiano (IT) (51.13 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/it/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_it.pdf)

latviešu valoda (LV) (81.63 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/lv/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_lv.pdf)

lietuvių kalba (LT) (82.54 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/lt/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_lt.pdf)

magyar (HU) (68.7 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/hu/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_hu.pdf)

Malti (MT) (84.23 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/mt/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_mt.pdf)

Nederlands (NL) (49.82 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/nl/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_nl.pdf)

polski (PL) (83.62 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/pl/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_pl.pdf)

português (PT) (49.74 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/pt/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_pt.pdf)

română (RO) (88.19 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/ro/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_ro.pdf)

slovenčina (SK) (81.5 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/sk/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_sk.pdf)

slovenščina (SL) (79.79 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/sl/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_sl.pdf)

Suomi (FI) (49.15 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/fi/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_fi.pdf)

svenska (SV) (50.18 KB - PDF)

**First published:**

01/10/2014

**Last updated:**

01/10/2014

[View](/sv/documents/scientific-conclusion/exforge-h-c-716-a31-0067-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisations-and-detailed-explanation-scientific-grounds-differences-prac-recommenda_sv.pdf)

Exforge-H-C-716-A31-0067 : EPAR - Assessment Report - Article 31

Adopted

English (EN) (301.42 KB - PDF)

**First published:** 01/10/2014

**Last updated:** 01/10/2014

[View](/en/documents/variation-report/exforge-h-c-716-a31-0067-epar-assessment-report-article-31_en.pdf)

Exforge-H-C-716-WS-0360 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/CHMP/356249/2013

English (EN) (329.42 KB - PDF)

**First published:** 11/12/2013

**Last updated:** 11/12/2013

[View](/en/documents/variation-report/exforge-h-c-716-ws-0360-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Exforge

Adopted

Reference Number: EMA/CHMP/388283/2013

English (EN) (68.5 KB - PDF)

**First published:** 28/06/2013

**Last updated:** 28/06/2013

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-exforge_en.pdf)

Exforge-H-C-716-WS-0100-G : EPAR - Assessment Report - Variation

Adopted

English (EN) (636.9 KB - PDF)

**First published:** 07/09/2011

**Last updated:** 07/09/2011

[View](/en/documents/variation-report/exforge-h-c-716-ws-0100-g-epar-assessment-report-variation_en.pdf)

## Initial marketing authorisation documents

Exforge : EPAR - Procedural steps taken before authorisation

English (EN) (23.32 KB - PDF)

**First published:** 21/02/2007

**Last updated:** 21/02/2007

[View](/en/documents/procedural-steps/exforge-epar-procedural-steps-taken-authorisation_en.pdf)

Exforge : EPAR - Scientific Discussion

English (EN) (333.19 KB - PDF)

**First published:** 21/02/2007

**Last updated:** 21/02/2007

[View](/en/documents/scientific-discussion/exforge-epar-scientific-discussion_en.pdf)

#### News on Exforge

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2013) 28/06/2013

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 13-16 May 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2013) 17/05/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 October 2011](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-october-2011) 21/10/2011

[European Medicines Agency concludes that benefit-risk balance of angiotensin-II-receptor antagonists remains positive](/en/news/european-medicines-agency-concludes-benefit-risk-balance-angiotensin-ii-receptor-antagonists-remains-positive) 20/10/2011

[European Medicines Agency recommendation on use of angiotensin-II-receptor antagonists during pregnancy](/en/news/european-medicines-agency-recommendation-use-angiotensin-ii-receptor-antagonists-during-pregnancy) 24/04/2008

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Exforge : EPAR - Product information - tracked changes

English (EN) (150.71 KB - DOCX)

**First published:** 19/11/2025

[View](/en/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-839)

български (BG) (150.13 KB - DOCX)

**First published:**

19/11/2025

[View](/bg/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_bg.docx)

español (ES) (164.91 KB - DOCX)

**First published:**

19/11/2025

[View](/es/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_es.docx)

čeština (CS) (144.81 KB - DOCX)

**First published:**

19/11/2025

[View](/cs/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (136.68 KB - DOCX)

**First published:**

19/11/2025

[View](/da/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (154.69 KB - DOCX)

**First published:**

19/11/2025

[View](/de/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (133.44 KB - DOCX)

**First published:**

19/11/2025

[View](/et/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (167.67 KB - DOCX)

**First published:**

19/11/2025

[View](/el/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_el.docx)

français (FR) (163 KB - DOCX)

**First published:**

19/11/2025

[View](/fr/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (144.8 KB - DOCX)

**First published:**

19/11/2025

[View](/hr/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (149.76 KB - DOCX)

**First published:**

19/11/2025

[View](/is/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_is.docx)

italiano (IT) (138.21 KB - DOCX)

**First published:**

19/11/2025

[View](/it/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (153.17 KB - DOCX)

**First published:**

19/11/2025

[View](/lv/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (153.65 KB - DOCX)

**First published:**

19/11/2025

[View](/lt/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (175.73 KB - DOCX)

**First published:**

19/11/2025

[View](/hu/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (151.93 KB - DOCX)

**First published:**

19/11/2025

[View](/mt/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (153.07 KB - DOCX)

**First published:**

19/11/2025

[View](/nl/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (148.58 KB - DOCX)

**First published:**

19/11/2025

[View](/no/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_no.docx)

polski (PL) (170.3 KB - DOCX)

**First published:**

19/11/2025

[View](/pl/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_pl.docx)

português (PT) (150.42 KB - DOCX)

**First published:**

19/11/2025

[View](/pt/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_pt.docx)

română (RO) (153.61 KB - DOCX)

**First published:**

19/11/2025

[View](/ro/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (150.01 KB - DOCX)

**First published:**

19/11/2025

[View](/sk/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (155.76 KB - DOCX)

**First published:**

19/11/2025

[View](/sl/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (148.16 KB - DOCX)

**First published:**

19/11/2025

[View](/fi/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (154.52 KB - DOCX)

**First published:**

19/11/2025

[View](/sv/documents/product-information-tracked-changes/exforge-epar-product-information-tracked-changes_sv.docx)

#### More information on Exforge

- [Valsartan containing medicinal products: Article 31 referrals](/en/medicines/human/referrals/sartan-medicines)
- [Renin-angiotensin-system (RAS)-acting agents: Article-31 referral](/en/medicines/human/referrals/renin-angiotensin-system-ras-acting-agents)

Questions and answers on the review of angiotensin-II-receptor antagonists and the risk of cancer

Reference Number: EMA/CHMP/834168/2011

English (EN) (511.41 KB - PDF)

**First published:** 20/10/2011

**Last updated:** 11/05/2017

[View](/en/documents/opinion-any-scientific-matter/questions-answers-review-angiotensin-ii-receptor-antagonists-risk-cancer_en.pdf)

#### More information on Exforge

- [EMEA-001680-PIP01-14 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001680-pip01-14)
- [Angiotensin-II-receptor antagonists (sartans) containing a tetrazole group - referral](/en/medicines/human/referrals/angiotensin-ii-receptor-antagonists-sartans-containing-tetrazole-group)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 19/11/2025

## Share this page

[Back to top](#main-content)